Skip to main content
. 2018 Apr 19;2018:9865495. doi: 10.1155/2018/9865495

Figure 1.

Figure 1

Troxerutin reduces ACR, ROS, and inflammatory lesion in the kidney of BDE-47-treated mice. (a) ACR level (albumin-to-creatinine, mg/g; n = 8) in BDE-47 mice including BDE-47 feeding and BDE-47/troxerutin were performed at 8 weeks. (b) ROS production was detected by fluorescent probe DCFH-DA. (c) Cytoplasm and nucleus NF-κB p65, iNOS, and COX-2 were examined by western blot. (d) shows the relative density analysis of cytoplasm and nucleus NF-κB p65, iNOS, and COX-2. The relative density is expressed as the ratio (iNOS/β-actin, COX-2/β-actin, cytoplasm NF-κB p65/β-actin, and nucleus NF-κB p65/H3). The control group is regarded as “1,” and all data are obtained at 8 weeks, which were the same as followed results of western blot. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001 versus the BDE-47 group (n = 5).